WD Rutherford LLC Has $1.77 Million Stock Position in Boston Scientific Corporation $BSX

WD Rutherford LLC grew its stake in Boston Scientific Corporation (NYSE:BSX) by 77.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 16,435 shares of the medical equipment provider’s stock after purchasing an additional 7,190 shares during the quarter. WD Rutherford LLC’s holdings in Boston Scientific were worth $1,765,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in shares of Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after purchasing an additional 3,932 shares during the period. NS Partners Ltd lifted its stake in shares of Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after purchasing an additional 5,704 shares during the period. Bank of New Hampshire lifted its stake in shares of Boston Scientific by 552.0% in the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after purchasing an additional 16,699 shares during the period. MRA Advisory Group acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $273,000. Finally, Neville Rodie & Shaw Inc. lifted its stake in shares of Boston Scientific by 95.9% in the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider’s stock valued at $4,883,000 after purchasing an additional 22,255 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $98.20 on Friday. The stock has a market cap of $145.51 billion, a PE ratio of 58.45, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65. The stock has a 50-day moving average price of $103.79 and a two-hundred day moving average price of $102.11. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s revenue for the quarter was up 22.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on BSX. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Robert W. Baird upped their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Leerink Partnrs upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Monday, June 16th. Leerink Partners began coverage on shares of Boston Scientific in a research report on Monday, June 16th. They issued an “outperform” rating and a $118.00 price objective for the company. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Boston Scientific in a research report on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $118.17.

Insider Buying and Selling

In other news, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $18,397,457 over the last 90 days. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.